Madrigal Pharmaceuticals (MDGL) Income from Continuing Operations (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Income from Continuing Operations of 57144000.0 for Q2 2026, down 35.17% year-over-year from 88147215.94 in Q2 2025, and up 38.09% quarter-over-quarter from 92299000.0 in Q1 2026.
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Income from Continuing Operations for 17 consecutive years, with 57144000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 35.17% year-over-year to 57144000.0; the TTM figure through Jun 2026 stood at 432537000.0 (down 61.2% YoY), while the FY2025 annual figure was 853782000.0, up 11.07% from the prior year.
- Income from Continuing Operations rose to 57144000.0 in Q2 2026 per MDGL's latest filing, from 92299000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 42275000.0 in Q2 2025 and bottomed at 171976000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 92741888.89 across 5 years, with a median of 85852500.0 in 2022.
- On a YoY basis, Income from Continuing Operations climbed as much as 72.18% in 2025 and fell as far as 275.12% in 2025.
- Madrigal Pharmaceuticals' Income from Continuing Operations stood at 85905000.0 in 2022, then sank by 30.6% to 112194000.0 in 2023, then soared by 59.14% to 45845000.0 in 2024, then tumbled by 275.12% to 171976000.0 in 2025, then soared by 66.77% to 57144000.0 in 2026.
- Business Quant data shows MDGL's Income from Continuing Operations at 57144000.0 in Q2 2026, 92299000.0 in Q1 2026, and 171976000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Madrigal Pharmaceuticals | 15.77 Bn | 14.93 Bn | - | -57.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -57.14 Mn |
| Mar 31, 2026 | -92.30 Mn |
| Dec 31, 2025 | -58.45 Mn |
| Sep 30, 2025 | -111.12 Mn |
| Jun 30, 2025 | -42.28 Mn |
| Mar 31, 2025 | -73.24 Mn |
| Dec 31, 2024 | -59.42 Mn |
| Sep 30, 2024 | -106.96 Mn |
| Jun 30, 2024 | -151.97 Mn |
| Mar 31, 2024 | -147.54 Mn |
| Dec 31, 2023 | -112.19 Mn |
| Sep 30, 2023 | -98.74 Mn |
| Jun 30, 2023 | -85.80 Mn |
| Mar 31, 2023 | -76.90 Mn |
| Dec 31, 2022 | -85.91 Mn |
| Sep 30, 2022 | -81.20 Mn |
| Jun 30, 2022 | -70.73 Mn |
| Mar 31, 2022 | -57.52 Mn |
| Dec 31, 2021 | -64.55 Mn |
| Sep 30, 2021 | -63.10 Mn |